0001731122-22-002078.txt : 20221202 0001731122-22-002078.hdr.sgml : 20221202 20221202081351 ACCESSION NUMBER: 0001731122-22-002078 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20221201 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221202 DATE AS OF CHANGE: 20221202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ANAVEX LIFE SCIENCES CORP. CENTRAL INDEX KEY: 0001314052 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 208365999 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37606 FILM NUMBER: 221440300 BUSINESS ADDRESS: STREET 1: 51 W 52ND STREET, STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019-6163 BUSINESS PHONE: 800-689-3939 MAIL ADDRESS: STREET 1: 51 W 52ND STREET, STREET 2: 7TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019-6163 FORMER COMPANY: FORMER CONFORMED NAME: Thrifty Printing Inc. DATE OF NAME CHANGE: 20050111 8-K 1 e4271_8-k.htm FORM 8-K
0001314052 false 0001314052 2022-12-01 2022-12-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 1, 2022

 

ANAVEX LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)

 

Nevada 001-37606 98-0608404
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

630 5th Avenue
20th Floor
New York, NY 10111
(Address of principal executive offices) (Zip Code)

 

1-844-689-3939

 (Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock, par value $0.001 per share AVXL The Nasdaq Stock Market LLC

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

  

Item 8.01 Other Events.

 

On December 1, 2022, Anavex Life Sciences Corp., a Nevada corporation (the “Company”) issued a press release (the “Press Release”) providing top line data from its Phase 2b/3 double-blind, placebo-controlled trial of ANAVEX®2-73 in Alzheimer’s disease. The trial met its primary and key secondary endpoints with statistically significant results. A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

  (d)  Exhibits

 

EXHIBIT NO.     DESCRIPTION   LOCATION
99.1     Press Release   Filed herewith

  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANAVEX LIFE SCIENCES CORP.
   
  By:  
    /s/Christopher Missling
    Name: Christopher Missling, PhD
    Title: Chief Executive Officer
     
 Date: December 2, 2022    

 

 

 

 

 

 EX-99.1 2 e4271_ex99-1.htm EXHIBIT 99.1

 

 

 EXHIBIT 99.1

 

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS, SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE

 

●Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL
●Key Secondary Endpoint CDR-SB Also Met, Demonstrating Statistically Significant Results
●Plan to Meet with Regulatory Authorities to Determine Next Steps

 

NEW YORK – December 1, 2022 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of oral ANAVEX®2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD). ANAVEX®2-73 met the primary endpoints ADAS-Cog[1] and ADCS-ADL[2] and key secondary endpoint CDR-SB[3] with statistically significant results. Next step, in light of this data, is meeting with regulatory authorities to discuss this data in the context of ongoing development with an aim to bring this therapy to patients in Europe, Asia-Pacific, and the U.S.

 

ANAVEX®2-73 (blarcamesine) is an orally available, small-molecule activator of the sigma-1 receptor (SIGMAR1), which, data suggest, is pivotal to restoring neural cell homeostasis and promoting neuroplasticity.[4]

 

ANAVEX®2-73-AD-004 was a randomized, double-blind, multicenter, placebo-controlled 509 patient Phase 2b/3 study (randomized 1:1:1 to mid or high dose of ANAVEX®2-73 or placebo), for the treatment of early Alzheimer’s disease over 48 weeks. Top line data will be presented later today in the late breaking oral communication presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022, December 1, 2022, at 4:30pm PT in San Francisco, CA. Further analysis of the data remains ongoing, and the Company plans to submit the data for publication in a peer-reviewed medical journal. The open-label extension study ATTENTION-AD will continue to follow participants over a 96 week period.

 

ANAVEX®2-73 treatment met the primary endpoints and reduced clinical decline on the global cognitive and functional scales over 48 weeks in the analysis of the Intent-to-treat (ITT) population.

 

[1] AD Assessment Scale-Cognitive subscale. ADAS-Cog is the most common cognitive assessment instrument used in AD clinical trials all over the world.

[2] AD Cooperative Study-Activities of Daily Living Scale. ADCS-ADL is the most common functional assessment instrument used in AD clinical trials all over the world.

[3] Clinical Dementia Rating-Sum of Boxes.

[4] Advances in Experimental Medicine and Biology Volume 964 (2017) Sigma Receptors: Their Role in Disease and as Therapeutic Targets.

 

 

 

 

ANAVEX®2-73 demonstrated visible improvement in patients with Alzheimer’s disease. Patients treated with ANAVEX®2-73 were 84% more likely, to have improved cognition by ADAS-Cog score change of -0.50 points or better from baseline to end of treatment than patients on placebo, Odds Ratio = 1.84 (p = 0.015). On average, patients, who improved cognitively with ANAVEX®2-73 treatment, improved by ADAS-Cog cognition score of -4.03 points. ANAVEX®2-73 treatment was 167% more likely to improve function compared with placebo, at a clinically meaningful improvement of ADCS-ADL score change of +3.5 points or better, Odds Ratio = 2.67 (p=0.0255). This reflects a robust improved and clinically meaningful outcome in cognition and function from baseline.

 

Additionally, treatment with ANAVEX®2-73 statistically significantly reduced cognitive decline, measured with ADAS-Cog, compared to placebo at end of treatment by 45%, representing a treatment difference in mean score change of -1.85 points (p=0.033).

 

ANAVEX®2-73 treatment also met the secondary endpoint of reduction in clinical decline of cognition and function assessed by the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) compared to placebo, by a treatment difference in mean score change of -0.42 points (p=0.040), representing 27% reduction in the ITT population.

 

ANAVEX®2-73 (blarcamesine) was generally safe and well tolerated. The incidence of treatment emergent adverse events (TEAEs) was similar in the active and placebo arms with dizziness being the most common TEAE. TEAEs ≥7.5% threshold were predominantly mild or moderate. No clinically significant changes in vital signs, laboratory values and ECG parameters in active and placebo arms were observed. Safety findings in the study were consistent with the known safety profile of ANAVEX®2-73.

 

In addition to safety and efficacy demonstrated on the primary and key secondary endpoints, a pre-specified analysis of patients without SIGMAR1 gene mutation provides further confidence of the robustness of the SIGMAR1 activation in the treatment of neurodegenerative diseases. Approximately 80% of the total worldwide population lack a SIGMAR1 gene mutation.[5] ANAVEX®2-73 was more efficacious in this pre-specified population. This effect is consistent with prior clinical trials of ANAVEX®2-73.[6]

 

“People living with Alzheimer’s disease desperately need new therapies and I am truly impressed with the outcome of this study, which demonstrated reversal of cognitive decline,” said A/Professor Stephen Macfarlane, FRANZCP, Head of Clinical Services at the Dementia Centre, HammondCare and Principal Investigator. “These results complement and are consistent with findings from the previously completed Alzheimer’s disease Phase 2a ANAVEX®2-73 trial, which also demonstrated therapeutic effect on cognition and function. ANAVEX®2-73 might be a very much needed solution for many patients with Alzheimer’s disease.”

 

“We are very pleased to see such positive clinical data in patients with Alzheimer’s disease, which is otherwise a progressive disease, thereby emphasizing the potentially significant implications these findings have for patients, caregivers, and healthcare systems worldwide,” said Edward R Hammond, MD, PhD, MPH, Chief Medical Officer of Anavex. “We intend to discuss these findings with regulatory authorities in the context of the ongoing clinical development of ANAVEX®2-73 in this indication, with the goal of providing a much-needed treatment to the millions of patients living with Alzheimer’s disease.”

 

[5] https://clinvarminer.genetics.utah.edu/variants-by-submitter/1012/gene/SIGMAR1/benign

[6] Hampel et al. A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer’s disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study. Alzheimer’s Dement. 2020;00:1–14

 

 

 

 

“The successful results of the ANAVEX®2-73-AD-004 clinical trial would not be possible without the truly motivated and dedicated study participants, their families and caregivers and the clinical investigators around the world. We thank all the people involved in the study for their invaluable contributions,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “These clinical study findings confirm the robustness of the ANAVEX precision medicine platform, and we look forward to advancing ANAVEX®2-73 as a potential new treatment option for Alzheimer’s disease while we continue to focus on the effect of ANAVEX®2-73 leveraging this approach to drug development to provide intelligent solutions beyond many traditional neurology trials in disease areas with high unmet needs.”

 

Economic Burden of Alzheimer's Disease[7]

Alzheimer's disease is the most common cause of dementia and the fifth leading cause of death in adults older than 65 years. The estimated total healthcare costs for the treatment of Alzheimer's disease in 2020 were estimated at $305 billion, with the cost expected to increase to more than $1 trillion as the population ages. Most of the direct costs of care for Alzheimer's disease are attributed to skilled nursing care, home healthcare, and hospice care. Indirect costs of care, including quality of life and informal caregiving, are likely underestimated, and are associated with significant negative societal and personal burdens.

 

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook, Instagram, and LinkedIn.

 

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

 

[7] W Wong Economic Burden of Alzheimer Disease and Managed Care Considerations Am J Manag Care. 2020;26:S177-S183.

 

 

 

 

For Further Information:

Anavex Life Sciences Corp.

Research & Business Development

Toll-free: 1-844-689-3939

Email: info@anavex.com

 

Investors:

Andrew J. Barwicki

Investor Relations

Tel: 516-662-9461

Email: andrew@barwicki.com

 

 

 

 

 EX-101.SCH 3 avxl-20221201.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 avxl-20221201_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 avxl-20221201_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Dec. 01, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 01, 2022
Entity File Number 001-37606
Entity Registrant Name ANAVEX LIFE SCIENCES CORP.
Entity Central Index Key 0001314052
Entity Tax Identification Number 98-0608404
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 630 5th Avenue
Entity Address, Address Line Two 20th Floor
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10111
City Area Code 844
Local Phone Number 689-3939
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol AVXL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 e4271_8-k_htm.xml IDEA: XBRL DOCUMENT 0001314052 2022-12-01 2022-12-01 iso4217:USD shares iso4217:USD shares 0001314052 false 8-K 2022-12-01 ANAVEX LIFE SCIENCES CORP. NV 001-37606 98-0608404 630 5th Avenue 20th Floor New York NY 10111 844 689-3939 false false false false Common Stock, par value $0.001 per share AVXL NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?2 M0$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N:I%FGJ:Q MJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L53,[E9C(, M]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I")\!K*_#, MU#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF"=9#;E9T M!N[RZ .;O\P>=0> M6N=6RKV'5[+E&''\GN4/4$L#!!0 ( +E!@E4D'INBK0 /@! : M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q= M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " "Y08)599!YDAD! #/ P M$P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M= M< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4' M3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!- MFI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXP MC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T, M:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( M +E!@E4'04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ N4&"53(-*6'N *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ N4&"59E&@$ @$0 & @($-" M>&PO=V]R:W-H965T&UL4$L! A0#% @ N4&"59^@&_"Q M @ X@P T ( !JPP 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ N4&"520>FZ*M M^ $ !H ( !T!$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( ! MM1( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ _Q, end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://anavex.com/role/Cover Cover Cover 1 false false All Reports Book All Reports e4271_8-k.htm avxl-20221201.xsd avxl-20221201_lab.xml avxl-20221201_pre.xml e4271_ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "e4271_8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "e4271_8-k.htm" ] }, "labelLink": { "local": [ "avxl-20221201_lab.xml" ] }, "presentationLink": { "local": [ "avxl-20221201_pre.xml" ] }, "schema": { "local": [ "avxl-20221201.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "AVXL", "nsuri": "http://anavex.com/20221201", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "e4271_8-k.htm", "contextRef": "From2022-12-01to2022-12-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://anavex.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "e4271_8-k.htm", "contextRef": "From2022-12-01to2022-12-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://anavex.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001731122-22-002078-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001731122-22-002078-xbrl.zip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end